The FDA accelerated approved Novartis AG's Fabhalta for reducing proteinuria in adults with IgAN. Approval is based on interim analysis, with ongoing study to confirm clinical benefits. Fabhalta showed promising results in reducing proteinuria and has a favorable safety profile.